Provides a 4-week supply to gently introduce the medication to your system
Too many patients focus on the starter price, commit to the platform, and then face sticker shock when the promotional period ends
One placebo-controlled trial revealed that weight loss injections treatments resulted in sustained body weight reductions for overweight and obese patients.1 The patients also made positive changes to their lifestyles during the study period
Underscoring the importance that direct cholesterol engagement has in the modulation of GLP-1R function, the changes in cholesterol binding and plasma membrane behaviours introduced by the V229A substitution led to significant effects on GLP-1R trafficking and signalling in beta cells: V229A caused a decrease in GLP-1R recruitment to CCPs and receptor internalisation, accompanied by an increase in G s (measured with mini-G s ) and -arrestin 2 engagement, as well as increased plasma membrane recycling following exendin-4 stimulation
Some individuals may attempt to use doses lower than the licensed starting doses or remain at the initial dose indefinitely, rather than following the licensed escalation protocol
Retatrutide is not FDA-approved, but our team can help eligible patients review medical weight loss options that may be available now, including tirzepatide and semaglutide when clinically appropriate
